However, mutations in the mTOR gene, as well as loss of function mutations in TSC1, TSC2 (tuberous sclerosis proteins 1 and 2), or STK11 (serine/threonine kinase 11), make cancer cells sensitive to mTOR inhibitors [171,172]. Here, STK11 is linked to cancer.